Literature DB >> 10497116

Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus.

L M Dunster1, H Wang, K D Ryman, B R Miller, S J Watowich, P D Minor, A D Barrett.   

Abstract

Six passages of the mosquito-borne flavivirus yellow fever (YF) wild-type strain Asibi in HeLa cells attenuated the virus for monkeys and newborn mice and resulted in loss of mosquito competence. Attenuation after the passage in HeLa cells was not unique to YF virus strain Asibi as demonstrated by the HeLa passage attenuation of wild-type YF virus strain French viscerotropic virus and YF vaccine virus 17D-204 for newborn mice. In contrast, wild-type strain Dakar 1279 and the French neurotropic vaccine virus remained virulent for newborn mice after six passages in HeLa cells. Thus not all strains of YF virus can be attenuated by passage in HeLa cells. Attenuation of YF virus strains Asibi and French viscerotropic virus was accompanied by alterations in the antigenic and biological properties of the viruses, including changes to envelope protein epitopes. Attenuation for newborn mice was coincidental with the acquisition by the HeLa-passaged viruses of the vaccine-specific envelope protein epitope recognized by monoclonal antibody H5. This suggests that this conformational change may play a role in the attenuation process. Wild-type Dakar 1279, which remained virulent for newborn mice after passage in HeLa cells, retained its wild-type antigenic character. The genome of Asibi HeLa p6 virus differed from wild-type Asibi virus by 29 nucleotides that encoded 10 amino acid substitutions: 5 in the envelope protein, 1 in NS2A, 3 in NS4B, and 1 in NS5. The substitution at NS4B-95 is seen in three different attenuation processes of wild-type YF virus, leading us to speculate that it is involved in the attenuation of virulence of wild-type strain Asibi.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497116     DOI: 10.1006/viro.1999.9873

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.

Authors:  S Bhardwaj; M Holbrook; R E Shope; A D Barrett; S J Watowich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Authors:  J E Blaney; D H Johnson; C Y Firestone; C T Hanson; B R Murphy; S S Whitehead
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus.

Authors:  Majid Laassri; Bella Bidzhieva; James Speicher; Alexander G Pletnev; Konstantin Chumakov
Journal:  J Med Virol       Date:  2011-02-25       Impact factor: 2.327

Review 5.  Yellow fever: a reemerging threat.

Authors:  Christina L Gardner; Kate D Ryman
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

6.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

Authors:  Jan-Jong Hung; Meng-Ti Hsieh; Ming-Jer Young; Chuan-Liang Kao; Chwan-Chuen King; Wen Chang
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing.

Authors:  Andrew Beck; Robert B Tesh; Thomas G Wood; Steven G Widen; Kate D Ryman; Alan D T Barrett
Journal:  J Infect Dis       Date:  2013-10-17       Impact factor: 5.226

9.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

10.  Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice.

Authors:  Michael Nickells; Thomas J Chambers
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.